Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate the potential benefits of the correction of growth hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure due to left ventricular systolic dysfunction.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federico II University
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Heart Failure in ew York Heart Association functional class II to IV

• Left ventricular end diastolic diameter > 60 mm

• Left ventricular ejection fraction < 40%

• Growth Hormone Deficiency (defined as a peak GH response to intravenous stimulation with GHRH + Arginine < 9 ng/dl)

• Age 18-80 years

• Clinical stability, guideline-oriented maximal pharmacological therapy

• Informed consent

Exclusion Criteria:

• Active Myocarditis

• Hypertrophic Cardiomyopathy

• Active endocarditis

• Active malignancy

• End stage renal disease

• Severe liver disease (Child B-C)